Besides collecting and freely sharing cancer genome data, research organizations and consortia are integrating genomic and clinical information and offering analytical tools.
Brooks Announces GENEWIZ Selected as Genome Characterization Center by the National Cancer Institute
News provided by
Share this article
Share this article
CHELMSFORD, Mass., Jan. 12, 2021 /PRNewswire/ Brooks Automation, Inc. (Nasdaq:BRKS) announced today that GENEWIZ, the Company s genomics analysis business, has been awarded one of six Genome Characterization Center Indefinite Delivery Indefinite Quantity (IDIQ) contracts from the National Cancer Institute (NCI). The NCI, the nation s leader in cancer research and part of the National Institutes of Health (NIH), chose GENEWIZ to provide whole exome sequencing to new research projects at its Center for Cancer Genomics for a period of three years.